| abstract |
Formula (I): [Chemical 1] Wherein R 1 is H, C 1-6 alkyl, —C (X) Y, C 3-8 cycloalkyl, aryl, Hetero, aryl-C 1-4 alkyl or hetero-C 1-4 alkyl, wherein cycloalkyl, aryl or hetero groups are optionally C 1-8 alkyl, C 1-8 alkoxy, OH, halo, CF 3 , at least one independently selected from OCF 3 , SCF 3 , hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S—C 1-4 alkyl Optionally substituted by two substituents; R 2 is aryl or heteroaryl, each optionally C 1-8 alkyl, C 1-8 alkoxy, OH, halo, CF 3 , OCF 3 , SCF 3 , Substituted with at least one substituent independently selected from hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl-S—C 1-4 alkyl Well; R 3 is C 1-6 alkyl, C 3-8 cycloal Kill, C 3-8 cycloalkyl-C 1-6 alkyl, aryl, hetero, aryl-C 1-4 alkyl or hetero-C 1-4 alkyl, wherein the cycloalkyl, aryl or hetero group is optionally C 1-6 alkyl, C 1-6 alkoxy, OH, halo, CF 3 , OCF 3 , SCF 3 , hydroxy-C 1-6 alkyl, C 1-4 alkoxy-C 1-6 alkyl and C 1-4 alkyl Optionally substituted with at least one substituent independently selected from —S—C 1-4 alkyl; X is S or O; Y is H, C 1-6 alkyl, aryl, hetero; Aryl-C 1-4 alkyl or hetero-C 1-4 alkyl; and n is 1 or 2, provided that when n is 1, m is 0 or 1 and n is 2. M is 0, and when m is 0, * represents a chiral center) And pharmaceutically and / or veterinary acceptable derivatives thereof. The compounds of the present invention exhibit activity as reuptake inhibitors of both serotonin and adrenaline and are therefore effective in various therapeutic fields, such as urinary incontinence treatment. |